EP0823912A1 - Derives d'azacycloalcanes, leur preparation et leurs applications en therapeutique - Google Patents
Derives d'azacycloalcanes, leur preparation et leurs applications en therapeutiqueInfo
- Publication number
- EP0823912A1 EP0823912A1 EP96913576A EP96913576A EP0823912A1 EP 0823912 A1 EP0823912 A1 EP 0823912A1 EP 96913576 A EP96913576 A EP 96913576A EP 96913576 A EP96913576 A EP 96913576A EP 0823912 A1 EP0823912 A1 EP 0823912A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- group
- phenylmethyl
- dihydro
- oxo
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
- C07D217/06—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Definitions
- the present invention relates to derivatives
- R 1 and R 2 identical or different, each represent a hydrogen atom, an alkyl group, linear, branched or cyclic, comprising from 1 to 6 carbon atoms, or a phenyl group optionally substituted by an alkyl group, linear or branched, comprising from 1 to 6 carbon atoms, by one or two halogen atoms or by a COOR 6 group, R 6 being a hydrogen atom or an alkyl group, linear or branched, comprising from 1 to 6 atoms of carbon,
- R 3 represents a hydrogen atom or an alkyl group, linear or branched, comprising from 1 to 4 carbon atoms, or else R 3 forms a methylene group,
- R 4 represents an aromatic group chosen from a phenyl, naphthyl or pyridinyl group, optionally substituted by an alkyl group, linear or branched, comprising from 1 to 6 carbon atoms, by one or two halogen atoms, by a nitro group , or by a COOR 6 group, R 6 being as defined above,
- R 4 represents a phenylene group in which a carbon atom is linked to Y and another carbon atom, adjacent to the preceding one, is linked to said methylene group
- R 5 is either an OR 7 group, where R 7 is a hydrogen atom or a benzyl group, or an N 4 - ethyl-piperazinyl group, or also an NHR 8 group where R 8 is a hydroxyl group,
- n 1 or 2
- A is an aromatic ring, optionally substituted by one or two halogen atoms, one or two alkyl groups, linear or branched, comprising from 1 to 4 carbon atoms, by a nitro group, by a COOR 6 , R 6 group being as defined above, by one or two alkoxy groups, linear or branched, comprising from 1 to 6 carbon atoms or by a methylenedioxy group,
- * X is CH, O or N, and * Y is CH 2 , O or S.
- the compounds of formula (I) form with the pharmaceutically acceptable acids and bases salts which form part of the invention.
- the preferred salts are the sodium and calcium salts, which are such that R 7 represents a sodium or calcium atom.
- the compounds of formula (I) have an asymmetric carbon atom. They can therefore exist in the form enantiomers. These enantiomers and their mixtures, including the racemic mixtures, form part of the invention.
- an aromatic group consists of an unsaturated ring comprising from 3 to 14 carbon atoms, as well as, optionally, a heteroatom chosen from the group consisting of sulfur, oxygen and nitrogen, said cycle having a maximum number of 'unsaturations, taking into account its possible substitutes.
- n is equal to 1 or 2
- the azacycloalkane derivative according to the invention is a dihydro-1H-pyrrole derivative.
- the azacycloalkane derivative according to the invention is a tetrahydropyridine derivative.
- A is chosen from the group consisting of thiophene, benzene, furan and naphthalene, these aromatic groups being or not substituted as indicated above.
- n is equal to 1 and R 5 is a hydroxyl group. Furthermore, R 4 is
- R 5 is as defined for formula (I) and R 9 and R 10 , identical or different, represent an atom
- the compounds of formula (I) can be prepared according to the process represented in scheme 1 in Annex 1. According to this process, a compound of formula (III) is reacted
- R 11 represents a halogen atom or a hydroxyl group
- R 12 is an alkoxy group comprising from 1 to 4 carbon atoms, linear or branched, or a phenylalkoxy group, the alkoxy part of which comprises from 1 to 4 carbon atoms, such as the benzyloxy group.
- This reaction can be carried out in a solvent such as dichloromethane, in the presence of triethylamine and / or an agent activating the acid function such as chloroformate.
- the compounds of the invention of formula (Ib), for which R 5 is a hydroxyl group can be obtained by hydrogenolysis or hydrolysis of the compounds of formula (la), using for example sodium hydroxide or hydrochloric acid.
- the compounds of the invention of formula (I) where R 5 is either an N 4 -methyl-piperazinyl group or an NHR 8 group where R 8 is a hydroxyl, pyridinylmethyl or phenylmethyl group can be prepared by reacting the compounds of formula (la) with an amine of formula HZ in which Z represents an N 4 -methyl-piperazinyl group or an NHR 8 group as defined above, in the presence of carbonyldiimidazole.
- the compounds of formula (III) can be prepared according to methods well known to those skilled in the art, in particular according to the methods described in the French patent application.
- the compounds of formula (III), in which A is an optionally substituted benzene group, n is equal to 1, R 1 and R 2 each represent a hydrogen atom can in particular be prepared according to the two methods represented in diagrams 2 and 3 of Annex 2.
- a compound of formula (V), in which R 13 represents a halogen atom, an NO 2 group, linear or branched alkyl, comprising from 1 to 4 carbon atoms with urea to prepare an imide compound of formula ( VI) where R 13 has the meaning indicated above.
- the imide function of the compound of formula (VI) is then reduced using sodium borohydride, in the presence of
- the compounds of formula (IV) can be prepared according to methods described in the literature, as for example in J. Am. Chem. Soc, 90, 3495-3502 (1968) or in J. Med. Chem., 36, 2788-2797 (1993).
- the analyzes confirm the structure of the compounds.
- This compound was obtained in the form of an oil, according to the process described in step 1.5 of Example 1, from phenylmethyl-3-carboxy-2 (S) - (phenylmethyl) -1-propanoate and 5-fluoro-2,3-dihydro-1H-isoindole.
- the mixture is refluxed for 5 h, cooled, 25 ml of methanol are added, the mixture is stirred for 1 h at room temperature, then 25 ml of 6N hydrochloric acid is added and the mixture is refluxed for 1 h.
- the mixture is filtered, the filtrate is concentrated, washed with twice 40 ml of diethyl ether and evaporated to dryness. 20 ml of a 5N sodium hydroxide solution are added and the mixture is extracted with twice 100 ml of dichloromethane. The organic phases are washed with brine, dried over sodium sulfate and then evaporated to dryness. 0.65 g of an oily product is obtained.
- This compound was obtained in the form of an oil, according to the process described in step 1.5 of Example 1, from phenylmethyl-3-carboxy-2 (S) - (phenylmethyl) -1-propanoate and 5-methyl-2,3-dihydro-1H-isoindole.
- This compound was obtained in the form of an oil, according to the process described in step 2.7 of Example 2, from 5-methyl- ⁇ -oxo- ⁇ (S) - (phenylmethyl) -2.3 -dihydro-1H-isoindole-2-phenylmethyl butanoate.
- the sodium salt of this compound has a melting point above 250 ° C.
- This compound was obtained in the form of a white solid, according to the process described in step 2.7 of Example 2, from ⁇ (R, S) - [[(2,3-dihydro-1H-isoindol -2- yl) carbonyl] amino] benzenepropanoate of phenylmethyl.
- This compound is obtained in the form of a white solid, according to the method described in step 1.6 of Example 1, from trans-3 - [(2,3-dihydro-1H-isoindol-2-yl) carbonyl] -1,2,3,4- ethyl tetrahydronaphthalene-2-carboxylate.
- the compounds of the invention are collated in the following table with their physical characteristics. They could have been prepared according to the methods described above.
- the compounds of the invention have been tested in various biological tests.
- This test is carried out on rats fasted for 20 h.
- the products to be tested are administered orally.
- Blood samples are taken from the tail 0.5, 1, 2, 3, 5 and 7 h after administration of the product, according to the method described by H. OHNOTA in The Journal of Pharmacology and Experimental Therapeutics, 269, n ⁇ 2, 489-495 (1994).
- the compounds of the invention reduce the basal blood sugar by 30 to 40% at doses between 1 and 10 mg / kg.
- any suitable excipient in any pharmaceutical form or composition suitable for oral or parenteral administration, for example, in the form of tablets, capsules, dragees, or oral solutions or
- the compounds of the invention can be administered in daily doses of between approximately 5 and 100 mg in adults by the oral route, or between approximately 1 and 100 mg by the parenteral route.
Abstract
Description
Claims
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9505260A FR2733750B1 (fr) | 1995-05-03 | 1995-05-03 | Derives de l'acide gamma-oxo-alpha-(phenylmethyl)-5,6- dihydro-4h-thieno(3,4-c)pyrrole-5-butanoique, leur preparation et leur application en therapeutique |
PCT/FR1996/000555 WO1996034870A1 (fr) | 1995-05-03 | 1996-04-12 | Derives d'azacycloalcanes, leur preparation et leurs applications en therapeutique |
FR9505260 | 1997-05-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
EP0823912A1 true EP0823912A1 (fr) | 1998-02-18 |
Family
ID=9478644
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP96913576A Withdrawn EP0823912A1 (fr) | 1995-05-03 | 1996-04-12 | Derives d'azacycloalcanes, leur preparation et leurs applications en therapeutique |
Country Status (22)
Country | Link |
---|---|
US (1) | US5869518A (fr) |
EP (1) | EP0823912A1 (fr) |
JP (1) | JPH11504913A (fr) |
KR (1) | KR19990008276A (fr) |
AR (1) | AR001838A1 (fr) |
AU (1) | AU699120B2 (fr) |
BG (1) | BG102015A (fr) |
BR (1) | BR9608309A (fr) |
CA (1) | CA2220015A1 (fr) |
CO (1) | CO4750652A1 (fr) |
CZ (1) | CZ346697A3 (fr) |
EE (1) | EE9700288A (fr) |
FR (1) | FR2733750B1 (fr) |
HU (1) | HUP9903886A3 (fr) |
IL (1) | IL118119A0 (fr) |
NO (1) | NO975020L (fr) |
NZ (1) | NZ307230A (fr) |
PL (1) | PL323177A1 (fr) |
SK (1) | SK147897A3 (fr) |
TR (1) | TR199701287T1 (fr) |
WO (1) | WO1996034870A1 (fr) |
ZA (1) | ZA963485B (fr) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0973778A1 (fr) * | 1997-03-07 | 2000-01-26 | Novo Nordisk A/S | DERIVES DE 4,5,6,7-TETRAHYDRO-THIENO 3,2-c]PYRIDINE, LEUR PREPARATION ET LEUR UTILISATION |
US6177443B1 (en) | 1997-03-07 | 2001-01-23 | Novo Nordisk A/S | 4,5,6,7-tetrahydro-thieno[3, 2-C]pyridine derivatives, their preparation and use |
WO1999045013A1 (fr) * | 1998-03-06 | 1999-09-10 | Novo Nordisk A/S | Derives de 4,5,6,7-tetrahydro-thieno[3,2-c]pyridine |
FR2777566B1 (fr) * | 1998-04-15 | 2003-02-21 | Synthelabo | Derives d'azacycloalcanes, leur preparation et leur application en therapeutique |
FR2779428B1 (fr) * | 1998-06-03 | 2001-05-18 | Synthelabo | Derives d'oxo-azacycloalcanes, leurs preparations et leurs applications en therapeutique |
US6090797A (en) * | 1998-09-02 | 2000-07-18 | Novo Nordisk A/S | 4,5,6,7-tetrahydro-thieno(2,3-C)pyridine derivatives |
AU5154699A (en) * | 1998-09-02 | 2000-03-27 | Novo Nordisk A/S | 4,5,6,7-tetrahydro-thieno(2,3-c)pyridine derivatives |
FR2793411B1 (fr) * | 1999-05-11 | 2001-06-29 | Synthelabo | Utilisation de derives de l'acide succinique pour obtenir un medicament destine au traitement de l'inflammation |
EP1088824B1 (fr) * | 1999-09-30 | 2004-01-07 | Pfizer Products Inc. | Amides de pyrrole bicycliques comme inhibiteurs du glycogène phosphorylase |
US6797820B2 (en) | 1999-12-17 | 2004-09-28 | Vicuron Pharmaceuticals Inc. | Succinate compounds, compositions and methods of use and preparation |
AR036053A1 (es) | 2001-06-15 | 2004-08-04 | Versicor Inc | Compuestos de n-formil-hidroxilamina, un proceso para su preparacion y composiciones farmaceuticas |
JP4314340B2 (ja) * | 2001-06-15 | 2009-08-12 | ヴィキュロン ファーマシューティカルズ インコーポレイテッド | ピロリジン二環性化合物 |
US20100113664A1 (en) * | 2008-06-11 | 2010-05-06 | Ferro Corporation | Asymmetric Cyclic Diester Compounds |
US20090312470A1 (en) * | 2008-06-11 | 2009-12-17 | Ferro Corporation | Asymmetric Cyclic Diester Compounds |
CA2739740A1 (fr) * | 2008-10-24 | 2010-04-29 | Gruenenthal Gmbh | 4,5,6,7-tetrahydrothienopyridines substituees, comme modulateurs des kcnq2/3 pour le traitement de la douleur, de l'epilepsie et de l'incontinence urinaire |
TW201238950A (en) | 2010-11-15 | 2012-10-01 | Abbott Lab | NAMPT and rock inhibitors |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3190950A (en) * | 1961-03-13 | 1965-06-22 | Acf Ind Inc | Pictorial position display |
US3706810A (en) * | 1970-09-15 | 1972-12-19 | American Cyanamid Co | N-morpholinoalkyl-thieno(3,2-b)pyrrole-5-carboxamides |
ZA821020B (en) * | 1981-02-18 | 1983-10-26 | Thomae Gmbh Dr K | Azepine derivatives, process for their preparation and pharmaceutical compositions thereof |
FR2537974A1 (fr) * | 1982-12-16 | 1984-06-22 | Adir | Nouveaux derives de thieno (2,3-b) pyrrole, leur procede de preparation et les compositions pharmaceutiques les renfermant |
FR2571723B1 (fr) * | 1984-10-12 | 1988-08-26 | Lipha | Derives de thieno et furo-(2,3-c) pyrroles, procedes de preparation et medicaments les contenant |
FR2652579B1 (fr) * | 1989-10-02 | 1992-01-24 | Sanofi Sa | Derives d'hydroxy-2 thiophene et furanne condenses avec un cycle azote, sur procede de preparation et leur application en therapeutique. |
FR2676446B1 (fr) * | 1991-05-17 | 1993-08-06 | Rhone Poulenc Rorer Sa | Nouveaux derives du thiopyranopyrrole, leur preparation et les compositions pharmaceutiques qui les contiennent. |
EP0599697A1 (fr) * | 1992-11-24 | 1994-06-01 | Synthelabo | Dérivés de pyrrole, leur préparation et leur application en thérapeutique |
FR2719844B1 (fr) * | 1994-05-10 | 1996-06-07 | Synthelabo | Dérivés de 5,6-dihydro-4h-thiéno[3,4-c]pyrrole, leur préparation et leur application en thérapeutique. |
-
1995
- 1995-05-03 FR FR9505260A patent/FR2733750B1/fr not_active Expired - Fee Related
-
1996
- 1996-04-12 BR BR9608309A patent/BR9608309A/pt not_active Application Discontinuation
- 1996-04-12 CZ CZ973466A patent/CZ346697A3/cs unknown
- 1996-04-12 JP JP8533065A patent/JPH11504913A/ja active Pending
- 1996-04-12 CA CA002220015A patent/CA2220015A1/fr not_active Abandoned
- 1996-04-12 KR KR1019970707802A patent/KR19990008276A/ko not_active Application Discontinuation
- 1996-04-12 AU AU56520/96A patent/AU699120B2/en not_active Ceased
- 1996-04-12 PL PL96323177A patent/PL323177A1/xx unknown
- 1996-04-12 NZ NZ307230A patent/NZ307230A/en unknown
- 1996-04-12 EP EP96913576A patent/EP0823912A1/fr not_active Withdrawn
- 1996-04-12 HU HU9903886A patent/HUP9903886A3/hu unknown
- 1996-04-12 US US08/945,576 patent/US5869518A/en not_active Expired - Fee Related
- 1996-04-12 EE EE9700288A patent/EE9700288A/xx unknown
- 1996-04-12 TR TR97/01287T patent/TR199701287T1/xx unknown
- 1996-04-12 WO PCT/FR1996/000555 patent/WO1996034870A1/fr not_active Application Discontinuation
- 1996-04-12 SK SK1478-97A patent/SK147897A3/sk unknown
- 1996-05-02 ZA ZA963485A patent/ZA963485B/xx unknown
- 1996-05-02 CO CO96021765A patent/CO4750652A1/es unknown
- 1996-05-02 AR AR33637996A patent/AR001838A1/es unknown
- 1996-05-02 IL IL11811996A patent/IL118119A0/xx unknown
-
1997
- 1997-10-31 NO NO975020A patent/NO975020L/no unknown
- 1997-11-03 BG BG102015A patent/BG102015A/xx unknown
Non-Patent Citations (1)
Title |
---|
See references of WO9634870A1 * |
Also Published As
Publication number | Publication date |
---|---|
AU699120B2 (en) | 1998-11-19 |
HUP9903886A2 (hu) | 2000-03-28 |
PL323177A1 (en) | 1998-03-16 |
FR2733750A1 (fr) | 1996-11-08 |
BR9608309A (pt) | 1999-01-26 |
IL118119A0 (en) | 1996-09-12 |
NO975020L (no) | 1998-01-05 |
CZ346697A3 (cs) | 1998-02-18 |
BG102015A (en) | 1998-08-31 |
AU5652096A (en) | 1996-11-21 |
CO4750652A1 (es) | 1999-03-31 |
NO975020D0 (no) | 1997-10-31 |
CA2220015A1 (fr) | 1996-11-07 |
HUP9903886A3 (en) | 2000-04-28 |
KR19990008276A (ko) | 1999-01-25 |
SK147897A3 (en) | 1998-05-06 |
FR2733750B1 (fr) | 1997-06-13 |
ZA963485B (en) | 1996-11-25 |
US5869518A (en) | 1999-02-09 |
WO1996034870A1 (fr) | 1996-11-07 |
JPH11504913A (ja) | 1999-05-11 |
EE9700288A (et) | 1998-04-15 |
MX9708322A (es) | 1998-06-28 |
AR001838A1 (es) | 1997-12-10 |
TR199701287T1 (xx) | 1998-03-21 |
NZ307230A (en) | 1998-11-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0202164B1 (fr) | Dérivés de (benzoyl-4 pipéridino)-2 phenyl-1 alcanols, leur préparation et leur application en thérapeutique | |
WO1996034870A1 (fr) | Derives d'azacycloalcanes, leur preparation et leurs applications en therapeutique | |
EP0522915B1 (fr) | Dérivés de pyrimidine-4-carboxamide, leur préparation et leur application en thérapeutique | |
FR2501686A1 (fr) | Nouveaux derives de 3,4-dihydro-5h-2,3-benzodiazepine, procede pour les preparer et medicaments les contenant | |
EP0005689B1 (fr) | Nouveaux acides lactame-N-acétiques et leurs amides, leurs procédés de préparation et compositions thérapeutiques | |
EP0306375A1 (fr) | Dérivés de[(pipéridinyl-4)méthyl]-2 tétrahydro-1,2,3,4 isoquinoléine, leur préparation et leur application en thérapeutique | |
WO1994015916A1 (fr) | Ligands selectifs des recepteurs 5ht1d-5ht1b derives d'indole-piperazine utiles comme medicaments | |
EP0351255B1 (fr) | Dérivés de [(pipéridinyl-4)méthyl]-2 tétrahydro-1,2,3,4 isoquinoléine, leur préparation et leur application en thérapeutique | |
EP0461958A1 (fr) | Dérivés de 2-(aminoalkyl)-5-(arylalkyl)-1,3-dioxanes, leur préparation et leur application en thérapeutique | |
EP0004494A1 (fr) | Nouveaux dérivés de 1,3-dihydro 3-(1-(2-(2,3-dihydro 1,4-benzo-dioxin-2-yl)2-hydroxy éthyl)pipéridin-4-yl)2H-indol 2-one, leur procédé de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant | |
FR2689509A1 (fr) | Nouveaux dérivés spiraniques du 3-amino chromane, leurs procédés de préparation et les compositions pharmaceutiques qui les contiennent. | |
EP0322263B1 (fr) | Carbamates tricycliques, leur procédé de préparation et leur application en thérapeutique | |
EP0500443B1 (fr) | Nouvelles phényléthanolamino- et phényléthanolaminométhyl-tétralines, procédé pour leur préparation, intermédiaires dans ce procédé et compositions pharmaceutiques les contenant | |
EP0486385A1 (fr) | Dérivés d'imidazole, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent | |
EP0138684B1 (fr) | 2-(N-pyrrolidino)-3-isobutoxy-N-phenyl substitué N-benzyl propylamines, leur préparation et leur application pharmaceutique | |
FR2463141A1 (fr) | Nouveaux derives de 10-halo-e-homoeburnane, procede de preparation de ces nouveaux derives et medicaments les contenant | |
FR2519982A1 (fr) | Nouveaux derives de l'indoline, leur preparation et leur utilisation comme medicaments | |
EP0233801B1 (fr) | Nouveaux amides substitués, leur préparation et les compositions pharmaceutiques qui les contiennent | |
EP0057337B1 (fr) | Dérivés du 4H-benzo(4,5)cyclohepta(1,2-b)furanne, leur procédé de préparation et leur application en tant que médicaments | |
EP0043811B1 (fr) | Nouvelles indolonaphtyridines et leur utilisation en tant que médicaments | |
EP0017523B1 (fr) | Nouveaux dérivés du dithiépinno (1,4)(2,3-c)pyrrole, leur préparation et les médicaments qui les contiennent | |
EP0351283A1 (fr) | Dérivés de [(pipéridinyl-4) méthyl]-2 dihydro-2,3 1H-isoindole et tétrahydro-2,3,4,5 1H-benzazépines, leur préparation et leur application en thérapeutique | |
CH620678A5 (en) | Process for the preparation of a derivative of piperidine | |
EP0300850B1 (fr) | Dérivés de 1-arylsulfonyl 1,5-dihydro 2H-pyrrol-2-one, leurs procédé et intermédiaires de préparation, leur application comme médicaments et les compositions les renfermant | |
FR2539412A1 (fr) | Derives du 5-fluoruracile et leurs utilisations therapeutiques en tant qu'agents carcinostatiques |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19971203 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE |
|
AX | Request for extension of the european patent |
Free format text: AL PAYMENT 971203;LT PAYMENT 971203;LV PAYMENT 971203;SI PAYMENT 971203 |
|
GRAG | Despatch of communication of intention to grant |
Free format text: ORIGINAL CODE: EPIDOS AGRA |
|
17Q | First examination report despatched |
Effective date: 19981215 |
|
GRAG | Despatch of communication of intention to grant |
Free format text: ORIGINAL CODE: EPIDOS AGRA |
|
GRAH | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOS IGRA |
|
GRAH | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOS IGRA |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 19990608 |